Received by email:

File: LLP-News Release -2017-02-21-Close PP.pdf

LeenLife Pharma International Inc.
Suite 380 - 580 Hornby Street
Vancouver, B.C., V6C 3B6



                                        NEWS RELEASE



     LeenLife Pharma International Closes Final Tranche of Private Placement

February 21, 2017                                                                               CSE - LLP

Vancouver, B.C.   LeenLife Pharma International Inc. (the "Company") is pleased to announce that it
has closed the final tranche (the "Final Tranche") of a non-brokered private placement offering of Units
(as defined below) previously announced on December 14, 2016 and January 6, 2017 (the "Private
Placements").

The closing of the Final Tranche resulted in gross proceeds to the Company of $473,000 from the sale of
4,730,000 units of the Company (the "Units"). The proceeds realized from the Final Tranche will be used
for general corporate and working capital purposes.

Each Unit was sold at a price of $0.10 and consists of one common share of the Company (each, a
"Common Share"), and one common share purchase warrant (each a "Warrant"). Each Warrant will be
exercisable into one Common Share at a price of $0.15 per Common Share for a period of two (2) years
from closing of the Final Tranche.

In total under the Private Placements, the Company issued 14,515,000 Units for aggregate gross
proceeds of $1,451,500. Certain registered brokers were paid a cash fee equal to 9% of the gross
proceeds they raised under the first and second tranches of the Private Placements. All securities issued
under the Final Tranche are subject to a statutory hold period of four months and one day from the
distribution date.

About LeenLife

LeenLife has acquired a proprietary process to isolate omega-3 fatty acids from flax seeds. LeenLife
products have been developed and researched for over 17 years. For additional information see our
website at http://leenlifepharma.com.

For more information, please contact:
Stan Lis, CEO
Tel: 604 764-0518
E-mail: slis@leenlifepharma.com

FORWARD LOOKING STATEMENTS
 Certain statements included in this press release constitute forward-looking information or statements (collectively,
"forward-looking statements"), including those identified by the expressions "anticipate", "believe", "plan",
"estimate", "expect", "intend", "may", "should" and similar expressions to the extent they relate to the Company or
its management. The forward-looking statements are not historical facts but reflect current expectations regarding
future results or events. These forward-looking statements are based on current expectations and various
estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors.

Readers should not place undue reliance on the Company's forward-looking statements, as the Company's actual
results, performance or achievements may differ materially from any future results, performance or achievements
expressed or implied by such forward-looking statements if known or unknown risks, uncertainties or other factors
affect the Company's business, or if the Company's estimates or assumptions prove inaccurate. Therefore, the
Company cannot provide any assurance that such forward-looking statements will materialize. Factors that could
cause actual results to differ materially from those in forward looking statements include, the timing and receipt of
government and regulatory approvals, and continued availability of capital and financing and general economic,
market or business conditions, loss of key directors, employees, and consultants and fees charged by service
providers. The forward-looking statements included in this news release are made as of the date hereof and the
Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise, except as expressly required by applicable securities laws.